With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year and switching focus to a second mRNA asset with GlaxoSmithKline.
A lot was expected from the little German biotech CureVac, with an mRNA shot on its hands, many were hoping the vaccine could match the heights seen by fellow/rival native BioNTech. But a botched first attempt that saw an efficacy range below 50%—far below the original 90% seen in early mRNA readouts from others—has pushed CureVac to finally toss that vaccine out.
